An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer

• Published in: Cancer letters Vol. 380; no. 1; pp. 144 - 152
• Main Authors: Premasekharan, Gayatri, Gilbert, Elizabeth, Okimoto, Ross A, Hamirani, Ashiya, Lindquist, Karla J, Ngo, Vy T, Roy, Ritu, Hough, Jeffrey, Edwards, Matthew, Paz, Rosa, Foye, Adam, Sood, Riddhi, Copren, Kirsten A, Gubens, Matthew, Small, Eric J, Bivona, Trever G, Collisson, Eric A, Friedlander, Terence W, Paris, Pamela L
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier Ireland Ltd 28.09.2016; Elsevier Limited
• Subjects: Biomarkers, Tumor - genetics; Biomarkers, Tumor - metabolism; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - metabolism; Carcinoma, Non-Small-Cell Lung - pathology; Carcinoma, Pancreatic Ductal - genetics; Carcinoma, Pancreatic Ductal - metabolism; Carcinoma, Pancreatic Ductal - pathology; Cell Adhesion; Cell adhesion matrix; Cell Line, Tumor; Cell Movement; Cell Separation - methods; Circulating tumor cells; Collagen - metabolism; Copy number; Deoxyribonucleic acid; DNA; DNA Mutational Analysis; Flow Cytometry; Fluorescence-activated cell sorting; Genes; Genetic Predisposition to Disease; Genomes; Genomics; Genomics - methods; Hematology, Oncology and Palliative Medicine; High-purity; High-Throughput Nucleotide Sequencing; Humans; Kinases; Lung cancer; Lung Neoplasms - genetics; Lung Neoplasms - metabolism; Lung Neoplasms - pathology; Male; Metastasis; Mutation; Neoplasm Invasiveness; Neoplastic Stem Cells - metabolism; Neoplastic Stem Cells - pathology; Pancreatic cancer; Pancreatic Neoplasms - genetics; Pancreatic Neoplasms - metabolism; Pancreatic Neoplasms - pathology; Patients; Phenotype; Prostate cancer; Prostatic Neoplasms, Castration-Resistant - genetics; Prostatic Neoplasms, Castration-Resistant - metabolism; Prostatic Neoplasms, Castration-Resistant - pathology; Receptor, Epidermal Growth Factor - genetics; Sequencing; EpCAM; Copy number; cytokeratin; FACS; iCTCs; aCGH; EGFR; prostate-specific membrane antigen; mCRPC; Circulating tumor cells; invasive circulating tumor cells; High-purity; Sequencing; CTCs; metastatic pancreatic cancer; PSA; metastatic castration resistant prostate cancer; next-generation sequencing; epidermal growth factor receptor; mPDAC; CK; EMT; CAM; whole genome amplification; WGA; Fluorescence-activated cell sorting; metastatic non-small cell lung cancer; PSMA; array comparative genomic hybridization; Cell adhesion matrix; epithelial to mesenchymal transition; mNSCLC; NGS; epithelial cell adhesion molecule; prostate-specific antigen
• ISSN: 0304-3835; 1872-7980
• DOI: 10.1016/j.canlet.2016.06.017

Highlights • A two-step CTC enrichment process to improve the purity of CTCs is reported. • Three different tumor types – prostate, lung and pancreas cancers – were evaluated. • Average iCTC purity from spiked-in cancer cell lines increased from 0.2 to 79.1%. • Average iCTC purity from metastatic cancer patients increased from 0.3 to 80.1%. • High purity iCTCs were compatible with various downstream genomic analyses.